Skip to main content
星昊医药 logo

星昊医药 — Investor Relations & Filings

Ticker · 920017 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2024-04-21 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920017

About 星昊医药

https://www.sunho.com.cn/

Beijing Sunho Pharmaceutical Co., Ltd. is a technology-driven enterprise specializing in the research, development, manufacturing, and commercialization of advanced pharmaceutical preparations. The company focuses on high-barrier drug delivery systems, including sustained-release, controlled-release, and complex injection technologies. Its core business encompasses the production of a diverse portfolio of chemical drugs and biological products, alongside comprehensive Contract Development and Manufacturing Organization (CDMO) services. Sunho Pharmaceutical operates modern, GMP-compliant production facilities designed to support the entire lifecycle of drug development, from pilot-scale testing to large-scale commercial manufacturing. By leveraging its proprietary formulation platforms, the company provides integrated solutions for complex dosage forms, catering to both domestic and international pharmaceutical markets.

Recent filings

Filing Released Lang Actions
北京星昊医药股份有限公司控股股东及其他关联方资金占用情况的专项说明
Regulatory Filings Classification · 95% confidence The document is a specialized explanatory statement regarding the use of funds by controlling shareholders and other related parties of Beijing Xinghao Pharmaceutical Co., Ltd. It references the audit report issued by Beijing Dahua International Certified Public Accountants for the fiscal year ending December 31, 2023. The document includes a detailed summary table of non-operating fund occupation and other related party fund transactions for 2023. It is issued pursuant to regulatory requirements from the China Securities Regulatory Commission and Beijing Stock Exchange concerning disclosure of related party transactions and fund occupation. The document is not a full annual report or audit report but a specific explanatory statement related to related party fund occupation, which is a type of regulatory disclosure. It contains substantive financial data and explanations but is focused on a particular aspect of financial disclosure rather than comprehensive financial statements. Given the nature of the document as a specialized explanatory statement on related party fund occupation, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory disclosures that do not fit other categories. The document is 9196 characters long, indicating it is a detailed disclosure rather than a brief announcement or certification letter.
2024-04-21 Chinese
2023年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2023 年年度报告" (2023 Annual Report) of Beijing Sunho Pharmaceutical Co., Ltd. It contains detailed sections typical of an annual report, including company overview, financial data and indicators, management discussion and analysis, major events, shareholder information, financing and profit distribution, board and senior management information, industry information, corporate governance, internal control, and financial accounting reports. The document includes comprehensive financial data, management analysis, risk factors, and detailed accounting figures for the full fiscal year 2023. The length of the document (15,000 characters) and the depth of content confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2023
2024-04-21 Chinese
独立董事2023年度述职报告（周均）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director 2023 Annual Report" and contains a detailed report of the independent director's duties, attendance, communications with auditors, and overall evaluation for the year 2023. It is a formal report on the independent director's activities and compliance with relevant laws and regulations. It is not an announcement of a report publication, nor is it a financial report or certification. The content focuses on board/management information, specifically the independent director's role and activities, which fits best under Board/Management Information (MANG). The document length is 2060 characters, which is relatively short but contains substantive content about management activities rather than just an announcement or certification. Therefore, the classification is MANG with high confidence.
2024-04-21 Chinese
关于注销部分股票期权的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing Xinghao Pharmaceutical Co., Ltd. regarding the cancellation of part of its stock options. It details the board and supervisory meetings that approved the cancellation, the procedures followed, and the regulatory compliance with stock incentive plans. The document does not contain financial statements or detailed financial performance data but focuses on corporate governance actions related to stock options. It is not a full annual or interim report, nor an earnings release or audit report. It is a formal announcement about a corporate action related to stock options, which fits best under the category of Regulatory Filings (RNS) as it does not fit other more specific categories like Director's Dealing or Share Issue/Capital Change, since it is about cancellation of stock options rather than issuance or insider trading. The document length is 3039 characters, which is relatively short and typical for an announcement rather than a full report.
2024-04-21 Chinese
独立董事2023年度述职报告（程雪翔）
Board/Management Information Classification · 95% confidence The document is an independent director's annual performance report for the year 2023, detailing the director's duties, attendance, opinions on board matters, communication with auditors, and protection of minority shareholders' rights. It is a detailed report on board/management activities and governance-related duties rather than a financial report or announcement. The document length is 3351 characters, which is relatively short but contains substantive content about the director's role and activities. It does not contain financial statements or earnings data, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a simple announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). The content fits best under Board/Management Information (MANG) as it relates to the independent director's report on their board duties and governance activities.
2024-04-21 Chinese
持股5%以上股东减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a shareholder holding more than 5% of the company's shares planning to reduce their holdings. It details the shareholder's identity, the number and percentage of shares held, the planned reduction amount, methods, timing, and compliance with relevant regulations. There is no financial data, earnings information, or management discussion. The document is a formal notification about a significant shareholder's planned share reduction, which fits the definition of a Major Shareholding Notification (MRQ). The document length is short and focused solely on this topic, confirming it is not a full report or earnings release but a specific notification about shareholding changes.
2024-04-09 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.